Filing Details
- Accession Number:
- 0000899243-20-020805
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-07-30 20:00:16
- Reporting Period:
- 2020-07-28
- Accepted Time:
- 2020-07-30 20:00:16
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1528115 | Annexon Inc. | ANNX | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1070844 | A Stephen Schwarzman | C/O The Blackstone Group Inc. 345 Park Avenue New York NY 10154 | No | No | Yes | No | |
1393818 | Blackstone Group Inc | 345 Park Avenue New York NY 10154 | No | No | Yes | No | |
1404071 | L.l.c. Management Group Blackstone | C/O The Blackstone Group Inc. 345 Park Avenue New York NY 10154 | No | No | Yes | No | |
1464695 | L.l.c. Gp I/Ii Holdings Blackstone | C/O The Blackstone Group Inc. 345 Park Avenue New York NY 10154 | No | No | Yes | No | |
1484870 | L.p. Ii Holdings Blackstone | C/O The Blackstone Group Inc. 345 Park Avenue New York NY 10154 | No | No | Yes | No | |
1597143 | Clarus Lifesciences Iii, L.p. | 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1620148 | Clarus Ventures Iii Gp, L.p. | 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1762202 | L.l.c. Iii Clarus Blackstone | C/O The Blackstone Group Inc. 345 Park Avenue New York NY 10154 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-07-28 | 643,208 | $0.00 | 643,208 | No | 4 | C | Indirect | See Footnotes |
Common Stock | Acquisiton | 2020-07-28 | 950,134 | $0.00 | 1,593,342 | No | 4 | C | Indirect | See Footnotes |
Common Stock | Acquisiton | 2020-07-28 | 697,860 | $0.00 | 2,291,202 | No | 4 | C | Indirect | See Footnotes |
Common Stock | Acquisiton | 2020-07-28 | 239,433 | $0.00 | 2,530,635 | No | 4 | C | Indirect | See Footnotes |
Common Stock | Acquisiton | 2020-07-28 | 200,000 | $17.00 | 2,730,635 | No | 4 | P | Indirect | See Footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Footnotes |
No | 4 | C | Indirect | See Footnotes |
No | 4 | C | Indirect | See Footnotes |
No | 4 | C | Indirect | See Footnotes |
No | 4 | P | Indirect | See Footnotes |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A-1 Redeemable Convertible Preferred Stock | Disposition | 2020-07-28 | 5,666,667 | $0.00 | 643,208 | $0.00 |
Common Stock | Series B Redeemable Convertible Preferred Stock | Disposition | 2020-07-28 | 8,370,685 | $0.00 | 950,134 | $0.00 |
Common Stock | Series C Redeemable Convertible Preferred Stock | Disposition | 2020-07-28 | 6,148,147 | $0.00 | 697,860 | $0.00 |
Common Stock | Series D Redeemable Convertible Preferred Stock | Disposition | 2020-07-28 | 2,109,407 | $0.00 | 239,433 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- The shares of Series A-1 Redeemable Convertible Preferred Stock of the Issuer were automatically converted on a 1-for-8.81 basis into common stock of the Issuer ("Common Stock") immediately prior to the closing of the Issuer's initial public offering.
- The shares of Series B Redeemable Convertible Preferred Stock of the Issuer were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
- The shares of Series C Redeemable Convertible Preferred Stock of the Issuer were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
- The shares of Series D Redeemable Convertible Preferred Stock of the Issuer were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
- Reflects securities held directly by Clarus Lifesciences III, L.P. Clarus Ventures III GP, L.P. is the general partner of Clarus Lifesciences III, L.P. Blackstone Clarus III L.L.C. is the general partner of Clarus Ventures III GP, L.P. The sole member of Blackstone Clarus III L.L.C. is Blackstone Holdings II L.P. The general partner of Blackstone Holdings II L.P. is Blackstone Holdings I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP L.L.C. is The Blackstone Group Inc. The sole holder of the Class C common stock of The Blackstone Group Inc. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by Blackstone's senior managing directors and controlled by its founder, Stephen A. Schwarzman.
- Information with respect to each of the Reporting Persons is given solely by such Reporting Person, and no Reporting Person has responsibility for the accuracy or completeness of information supplied by another Reporting Person.
- Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.